Protagonist (PTGX) falls 0.73% to Close at $45.06 on September 14

Equities Staff  |

Protagonist Therapeutics Inc (NASDAQ: PTGX) shares fell 0.73%, or $0.33 per share, to close Tuesday at $45.06. After opening the day at $45.39, shares of Protagonist fluctuated between $46.13 and $45.00. 309,121 shares traded hands an increase from their 30 day average of 273,498. Tuesday's activity brought Protagonist’s market cap to $2,142,628,819.

About Protagonist Therapeutics Inc

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.

Visit Protagonist Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Protagonist Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Protagonist Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

President Biden's New Alliance With Australia and Britain Angers France and European Union
California Governor Newsom Signs Affordable Housing Law
COVID-19 Surge in Idaho Forcing Statewide Health Care Rationing
JPMorgan Launching Its First Overseas Digital Bank in United Kingdom Next Week
Federal Reserve Reviewing Ethics Policies in Wake of Prolific Trading Disclosed by Two Senior Officials
Chinese Property Developer Evergrande Not 'Too Big to Fail' — Global Times
August Retail Sales Rebound 0.7%, Surprising Economists After July Plunge
UN Report Shows COVID-19 Has Not Slowed Pace of Climate Change



Market Movers

Sponsored Financial Content